NASDAQ$CABA
Cabaletta Bio Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Cabaletta Bio reported financial results for Q1 2024 and provided a business update.
Cabaletta Bio reported first quarter 2024 financial results, highlighting the progress of CABA-201 clinical trials and advancements in optimizing patient experience, along with upcoming presentations of initial clinical data.
- No CRS or ICANS of any grade were observed in either of the first patients dosed with CABA-201 in the RESET-Myositis and RESET-SLE trials.
- Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials will be presented at a satellite symposium at the EULAR 2024 Congress in June.
- Cabaletta is evaluating CABA-201 without preconditioning by initiation of the RESET-PV sub-study within the ongoing DesCAARTes trial in pemphigus vulgaris.
- The company demonstrated the potential to eliminate the need for apheresis by using a blood draw to obtain the starting material for the CABA-201 manufacturing process.
Headline financials
Revenue & EPS history
Cabaletta Bio · Revenue · Quarterly
$0
Forward guidance
Cabaletta Bio expects that its cash, cash equivalents and short-term investments as of March 31, 2024, will enable it to fund its operating plan into the first half of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+2.7%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+5.3%
Avg return
30 days after
67%
16 / 24 earnings
Positive
+22.7%
Q3 2022
Best reaction
-24.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -7.8% | -9.0% | -16.2% | |
| Q3 2025 | -5.0% | -9.4% | -5.1% | |
| Q1 2025 | -0.6% | +6.9% | -2.9% | |
| Q4 2024 | +12.8% | -28.4% | -14.8% | |
| Q3 2024 | -24.4% | -36.7% | -29.7% | |
| Q1 2024 | +12.4% | +14.7% | -5.1% | |
| Q4 2023 | -4.2% | -6.4% | -26.4% | |
| Q3 2023 | +4.0% | +1.6% | -5.6% | |
| Q2 2023 | +10.0% | +10.4% | +12.0% | |
| Q1 2023 | +1.6% | +7.0% | -1.2% | |
| Q4 2022 | +9.3% | +4.3% | +5.4% | |
| Q3 2022 | +22.7% | +84.0% | +207.2% | |
| Q2 2022 | +19.5% | +17.2% | -26.3% | |
| Q1 2022 | +21.1% | +52.8% | -3.3% | |
| Q4 2021 | +14.6% | +32.7% | +6.4% | |
| Q3 2021 | +2.4% | -5.3% | -19.1% | |
| Q2 2021 | +2.0% | +1.9% | +58.0% | |
| Q1 2021 | -6.6% | -14.0% | -7.2% | |
| Q4 2020 | +1.7% | -4.0% | -8.7% | |
| Q3 2020 | +6.7% | +7.1% | +19.3% | |
| Q2 2020 | +6.4% | +4.6% | -15.8% | |
| Q1 2020 | -9.3% | -8.0% | -8.0% | |
| Q4 2019 | +0.3% | -7.6% | +10.7% | |
| Q3 2019 | -23.7% | -38.7% | +3.7% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro